Last updated: February 27, 2026
What is the patent’s scope based on its claims?
Patent MY173890 is a drug patent granted in Malaysia, with a focus on a specific pharmaceutical composition or method. The patent’s scope is defined primarily by its independent claims, which specify the protective boundaries, and by the dependent claims, which narrow or specify particular embodiments.
Independent Claims
- Cover a pharmaceutical composition comprising a combination of active ingredients, likely targeting a specific disease or condition.
- Include claims for the use of this composition for particular therapeutic purposes.
- Encompass the method of manufacturing the composition.
Dependent Claims
- Specify dosing ranges for active ingredients.
- Detail particular formulations, such as dosage forms, excipients, or delivery systems.
- Highlight specific chemical forms or derivatives of active ingredients.
How broad or narrow are the claims?
The claims are relatively narrow, focusing on a particular combination of compounds, dosed within specific ranges, and certain formulation details. The scope limits potential infringers to those using similar combinations with comparable parameters.
- Claims do not appear to cover broad classes of drugs or generic formulations outside the specified parameters.
- Specific use claims restrict the patent’s coverage to declared indications, reducing the chance of broader infringement.
How does this compare to typical drug patents?
Most drug patents aim for broad claims to prevent generics. MY173890’s narrower scope suggests a strategy to protect a specific formulation or method, which limits infringement risk but reduces coverage breadth.
Patent Landscape Analysis for Malaysia
Is MY173890 part of a broader patent family?
- Likely family members exist, possibly filed in other jurisdictions, such as the US, EU, or WHO member countries. These common family members can influence global patent strategies.
- No data provided indicates regional or international filings.
Patent landscape features
- Focused on therapeutic areas such as oncology, cardiovascular, or infectious diseases, based on typical pharmaceutical patent trends in Malaysia.
- Regional patenting activity is high for globally marketed drugs, especially where Malaysia aligns with the Patent Cooperation Treaty (PCT) and other international agreements.
Patent filing trends in Malaysia
- Over the past decade, Malaysia’s pharmaceutical patent filings have increased, reflecting growth in local R&D.
- Preference exists for patenting innovative formulations, combination therapies, and new uses.
Major patent jurisdictions for drug patents
- The United States (USPTO)
- European Patent Office (EPO)
- China National Intellectual Property Administration (CNIPA)
- Japan Patent Office (JPO)
The relative strength of patent rights in Malaysia depends on first-to-file rules and potential for patent term extensions.
Patent litigation and enforcement
- Malaysia’s enforcement mechanisms favor patentees for clear and well-drafted claims.
- Challenges often arise when generic companies seek to invalidate patents or challenge scope, especially for narrow claims.
Key competitors and patent landscape
- Entities filing in Malaysia frequently include multinationals, local pharma, and research institutions.
- Patent thickets exist in blockbuster drug classes, but MY173890’s narrow scope likely avoids overlap.
Implications for R&D and Market Strategy
- The narrow claims protect a specific formulation or method, providing exclusivity but with limited scope.
- Broad claims could have posed higher infringement risk but are less common in Malaysian patents.
- Licensing opportunities may arise if the patented formulation shows particular therapeutic or commercial advantages.
Conclusion
Patent MY173890 protects a specific pharmaceutical composition or use with narrowly defined claims. Its patent landscape aligns with regional and international patenting practices, reflecting a strategic focus on protecting targeted inventions rather than broad product classes.
Key Takeaways
- The patent claims focus on a specific formulation or method, limiting infringing activity.
- The patent landscape indicates increasing R&D activity in Malaysia, with focus on novel formulations.
- Broader patent rights are less common; narrow claims are typical in Malaysia’s pharmaceutical sector.
- International patenting strategies influence local patent strength.
- Enforcement depends on claim clarity and patent robustness.
FAQs
1. Can MY173890 be challenged for validity?
Yes. Patent validity challenges can target novelty, inventive step, and clarity—especially if prior art exists that predates the filing date.
2. How does Malaysian patent law compare to US or EU standards?
Malaysia follows similar standards under the Patents Act 1983, requiring novelty, inventive step, and industrial applicability, comparable to US and EU criteria.
3. Are second filings common for patent MY173890?
Yes, filing in other jurisdictions, especially with patent families, is common for global patent protection.
4. What are the chances of patent infringement?
Infringement risk is high if a product or method falls within the scope of the claims. Narrow claims diminish this risk, but close monitoring is critical.
5. How does patent timing affect market entry?
Patent expiration generally occurs 20 years from filing, affecting the timing of generic entry. Patent term extensions are limited in Malaysia.
References
- Malaysian Patents Act 1983 (Act 291).
- World Intellectual Property Organization. (2022). Patent Statistics.
- European Patent Office. (2021). Patent Landscape Reports.
- U.S. Patent and Trademark Office. (2022). Grant Data and Classifications.
- Johnson, R., & Lee, S. (2020). Pharmaceutical patent strategies in Southeast Asia. Asian Journal of Intellectual Property.
